EMAIL THIS PAGE TO A FRIEND

PloS one

¹H-NMR and MS based metabolomics study of the intervention effect of curcumin on hyperlipidemia mice induced by high-fat diet.


PMID 25786031

Abstract

Curcumin, a principle bioactive component of Curcuma longa L, is well known for its anti-hyperlipidemia effect. However, no holistic metabolic information of curcumin on hyperlipidemia models has been revealed, which may provide us an insight into the underlying mechanism. In the present work, NMR and MS based metabolomics was conducted to investigate the intervention effect of curcumin on hyperlipidemia mice induced by high-fat diet (HFD) feeding for 12 weeks. The HFD induced animals were orally administered with curcumin (40, 80 mg/kg) or lovastatin (30 mg/kg, positive control) once a day during the inducing period. Serum biochemistry assay of TC, TG, LDL-c, and HDL-c was conducted and proved that treatment of curcumin or lovastatin can significantly improve the lipid profiles. Subsequently, metabolomics analysis was carried out for urine samples. Orthogonal Partial Least Squares-Discriminant analysis (OPLS-DA) was employed to investigate the anti-hyperlipidemia effect of curcumin and to detect related potential biomarkers. Totally, 35 biomarkers were identified, including 31 by NMR and nine by MS (five by both). It turned out that curcumin treatment can partially recover the metabolism disorders induced by HFD, with the following metabolic pathways involved: TCA cycle, glycolysis and gluconeogenesis, synthesis of ketone bodies and cholesterol, ketogenesis of branched chain amino acid, choline metabolism, and fatty acid metabolism. Besides, NMR and MS based metabolomics proved to be powerful tools in investigating pharmacodynamics effect of natural products and underlying mechanisms.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

93791
Allantoin, analytical standard
C4H6N4O3
A0349000
Allantoin, European Pharmacopoeia (EP) Reference Standard
C4H6N4O3
PHR1364
Allantoin, Pharmaceutical Secondary Standard; Certified Reference Material
C4H6N4O3
05670
Allantoin, ≥98.0% (N)
C4H6N4O3
H6132
DL-3-Hydroxy-3-methylglutaryl coenzyme A sodium salt hydrate, ≥90% (HPLC)
C27H42N7Na2O20P3S · xH2O
94640
DL-Valine, ReagentPlus®, ≥99.0% (NT)
C5H11NO2
V0375
DL-Valine, ≥97% (TLC)
C5H11NO2
W344400
DL-Valine, ≥97%
C5H11NO2
I0460000
Isoleucine, European Pharmacopoeia (EP) Reference Standard
C6H13NO2
W527602
L-Isoleucine, 99%, FCC, FG
C6H13NO2
I5281
L-Isoleucine, PharmaGrade, Ajinomoto, EP, JP, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture
C6H13NO2
I2752
L-Isoleucine, reagent grade, ≥98% (HPLC)
C6H13NO2
PHR1099
L-Isoleucine, Pharmaceutical Secondary Standard; Certified Reference Material
C6H13NO2
I7403
L-Isoleucine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
C6H13NO2
58879
L-Isoleucine, BioUltra, ≥99.5% (NT)
C6H13NO2
56241
L-Isoleucine, certified reference material, TraceCERT®
C6H13NO2
I2877
L-Isoleucine: D-allo-isoleucine
C6H13NO2
P0064
PalGly, ≥98% (HPLC), solid
C18H35NO3
PHR1109
Taurine, Pharmaceutical Secondary Standard; Certified Reference Material
C2H7NO3S
1643361
Taurine, United States Pharmacopeia (USP) Reference Standard
C2H7NO3S
V0030000
Valine, European Pharmacopoeia (EP) Reference Standard
C5H11NO2